From the Journals
Can Liver-Only Targeting Change Lipids?
-
By
January 20, 2026
-
2 min
-
1
TLC-2716 targets triglyceride-rich lipoproteins.
-
2
It is a liver X receptor inverse agonist.
-
3
Phase 1 trial involved 100 healthy volunteers.
-
4
Up to 38% reduction in triglycerides noted.
-
5
Safety profile showed no serious adverse events.
-
6
Side effects were mostly mild.
-
7
Long-term studies are necessary for clinical benefit evaluation.
-
TLC-2716 is an investigational oral medication targeting triglyceride-rich lipoproteins, primarily acting in the liver and gut. Developed as a liver X receptor inverse agonist, it aims to enhance lipid profiles while minimizing systemic exposure. Early data from a phase 1 trial involving 100 healthy volunteers indicates significant reductions in triglycerides (up to 38%) and remnant cholesterol (up to 61%) at doses of 6mg and 12mg, while demonstrating a favorable safety profile with no serious adverse events. Further long-term studies are required to assess clinical outcomes.
-
1
TLC-2716 targets triglyceride-rich lipoproteins.
-
2
It is a liver X receptor inverse agonist.
-
3
Phase 1 trial involved 100 healthy volunteers.
-
4
Up to 38% reduction in triglycerides noted.
-
5
Safety profile showed no serious adverse events.
-
6
Side effects were mostly mild.
-
7
Long-term studies are necessary for clinical benefit evaluation.
Listen Tab content
